Regencell (NASDAQ: RGC) director holds option for 592,230 shares

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd reported the initial holdings of director Dr. William Wing Yan Lo on a Form 3. The filing shows he holds a stock option to purchase 592,230 ordinary shares at an exercise price of $0.84 per share.

The option was granted on January 1, 2022 under the company’s 2021 Share Option Plan, vested in equal installments over four anniversaries of the grant date, and is now fully vested. The option expires on December 31, 2032. The Form 3 reflects existing derivative holdings rather than a new market buy or sell.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LO WILLIAM WING YAN DR

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to purchase)	--	--	--

Holdings After Transaction: Stock option (right to purchase) — 592,230 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LO WILLIAM WING YAN DR

(Last) (First) (Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to purchase)	(1)	12/31/2032	Ordinary shares, par value $0.00001	592,230	$0.84	D

Explanation of Responses:

1. The Reporting Person was granted the option on January 1, 2022 pursuant to the Issuer's 2021 Share Option Plan. The option vested equally each of the four anniversaries of the grant date and is now fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Wai Hong Chung, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does Regencell (RGC) disclose for Dr. William Lo on this Form 3?

The Form 3 shows Dr. William Lo holds a stock option over 592,230 ordinary shares of Regencell. This is an initial disclosure of his derivative holdings as a director, not a record of a recent purchase or sale.

What are the key terms of Dr. William Lo’s Regencell (RGC) stock option?

Dr. Lo’s option covers 592,230 ordinary shares with an exercise price of $0.84 per share. It was granted on January 1, 2022, under the 2021 Share Option Plan and is now fully vested with an expiration date of December 31, 2032.

Does this Regencell (RGC) Form 3 show any insider buying or selling activity?

The Form 3 does not show insider buying or selling. It records Dr. Lo’s existing stock option holding as an initial statement of beneficial ownership, reflecting a derivative position rather than a new market transaction in Regencell shares.

How did Dr. William Lo’s Regencell (RGC) stock option vest over time?

The option granted to Dr. Lo on January 1, 2022 vested in four equal installments on each anniversary of the grant date. According to the disclosure, the option is now fully vested, meaning all 592,230 underlying shares are currently exercisable.

When does Dr. William Lo’s Regencell (RGC) stock option expire?

Dr. Lo’s Regencell stock option expires on December 31, 2032. Until that date, subject to plan terms, he may exercise the option to buy up to 592,230 ordinary shares at the fixed exercise price of $0.84 per share.